Reach the investors backing rounds like this
Backed by AbbVie · verified emails and LinkedIn on Datapile
AbbVie discloses up to $757M deal with Beijing-based Brise for preclinical migraine meds - Endpoints News
Brise Pharma, a Beijing-based company, has entered into a discovery and commercialization deal with AbbVie for two preclinical migraine programs. This partnership aims to advance the development of novel treatments for migraine.
AbbVie discloses up to $757M deal with Beijing-based Brise for preclinical migraine meds Endpoints News
| Nov 03, 2026 | Gongji Technology | $45.1M | Early VC | China |
| Nov 02, 2026 | High Energy Digital | $15.0M | Series B | China |
| Nov 02, 2026 | GenRobot AI | $100.0M | Series A+ | China |
| Oct 30, 2026 | GlassCore | $25.5M | Series B | China |
You just read who funded Brise Pharma. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.